Mounjaro vs Ozempic: Which Is Stronger?
These are the diabetes-branded versions — but they're searched constantly for weight loss. Here's how they really compare.
Mounjaro is tirzepatide; Ozempic is semaglutide. Both are once-weekly injections FDA-approved for type 2 diabetes, and both are widely used off-label or via their sibling brands for weight loss. The key difference is the same single-vs-dual story.
| Mounjaro | Ozempic | |
|---|---|---|
| Drug | Tirzepatide | Semaglutide |
| Mechanism | Dual GIP + GLP-1 | Single GLP-1 |
| Approved for | Type 2 diabetes | Type 2 diabetes; CV risk reduction |
| Weight-loss sibling | Zepbound | Wegovy |
| Max dose | 15 mg/week | 2.0 mg/week |
Which produces stronger results?
Tirzepatide's dual mechanism generally produces greater A1C reduction and weight loss on average. In head-to-head weight-loss research (SURMOUNT-5, comparing the weight-loss brands Zepbound and Wegovy), tirzepatide came out ahead — roughly 20% vs 14% average body-weight loss. For blood sugar, tirzepatide has also shown strong A1C lowering.
Important framing
Ozempic and Mounjaro are approved for diabetes, not weight loss. If weight loss is your goal, the on-label products are Wegovy and Zepbound. People search the diabetes names out of familiarity, but a provider will prescribe the appropriate product for your situation.
Side effects and safety
Both share the GLP-1 side-effect profile: mostly GI symptoms early on, a boxed thyroid-tumor warning, and cautions around pancreatitis, gallbladder disease, and low blood sugar when combined with insulin or sulfonylureas.
Wondering which is right for you?
A licensed provider can review your health online and recommend an appropriate, affordable option. Check eligibility free.
Check Your Eligibility